ANGLE plc ("the Company")DNA ANALYSIS OF PARSORTIX-ENRICHED CTCS AND CTDNA PROVIDES COMPLEMENTARY INFORMATION IN NSCLC PATIENTS TREATED WITH ASTRAZENECA'S OSIMERTINIBThe…
GENEVA, SWITZERLAND / ACCESSWIRE / November 11, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical…
Q3 Financial PerformanceDenver, Colorado--(Newsfile Corp. - November 10, 2024) - CBD of Denver (OTC Pink: CBDD) is pleased to report…
RIYADH, Saudi Arabia, Nov. 10, 2024 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) announced a significant…
ALK (ALKB:DC / OMX: ALK B) today announced that it has entered into a strategic license agreement with US-based ARS…
Data presented in an oral session at the Society for Immunotherapy of Cancer 39th Annual Meeting, where it was selected…
Novel H2CasMab-2 Antigen Binding Domain Shown to Preferentially Target HER2 Expressed on Tumor Cells in Preclinical Studies Initial Low-Dose Cohort…
Oral presentation highlighting IGNYTE primary analysis data shows anti-tumor activity across all subgroups with injected and non-injected lesions responding with…
Phase 1/2 data show improvements across all domains and confirm that Phase 3 Aspire study is amply powered to establish…
Ironsail Pharma’s mission is to enhance patient outcomes by connecting providers and pharmacies through a technology-driven solution that emphasizes transparency…